OCUL
Income statement / Annual
Last year (2023), Ocular Therapeutix, Inc.'s total revenue was $58.44 M,
an increase of 13.49% from the previous year.
In 2023, Ocular Therapeutix, Inc.'s net income was -$80.74 M.
See Ocular Therapeutix, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$58.44 M
|
$51.49 M
|
$43.52 M
|
$17.40 M
|
$4.23 M
|
$1.99 M
|
$1.92 M
|
$1.89 M
|
$1.75 M
|
$772,000.00
|
| Cost of Revenue |
$5.28 M |
$4.54 M |
$4.41 M |
$2.08 M |
$2.33 M |
$465,000.00 |
$457,000.00 |
$443,000.00 |
$319,000.00 |
$91,000.00 |
| Gross Profit |
$53.16 M |
$46.95 M |
$39.12 M |
$15.32 M |
$1.90 M |
$1.53 M |
$1.47 M |
$1.44 M |
$1.43 M |
$681,000.00 |
| Gross Profit Ratio |
0.91 |
0.91 |
0.9 |
0.88 |
0.45 |
0.77 |
0.76 |
0.77 |
0.82 |
0.88 |
| Research and Development
Expenses |
$61.06 M
|
$53.46 M
|
$50.08 M
|
$28.69 M
|
$41.09 M
|
$36.92 M
|
$30.88 M
|
$27.07 M
|
$26.61 M
|
$18.88 M
|
| General & Administrative
Expenses |
$33.94 M
|
$32.22 M
|
$31.88 M
|
$22.86 M
|
$22.12 M
|
$18.79 M
|
$15.51 M
|
$11.00 M
|
$9.17 M
|
$6.91 M
|
| Selling & Marketing
Expenses |
$40.55 M
|
$39.92 M
|
$35.19 M
|
$26.61 M
|
$24.49 M
|
$4.94 M
|
$17.00 M
|
$6.70 M
|
$3.85 M
|
$1.98 M
|
| Selling, General &
Administrative Expenses |
$74.49 M
|
$72.15 M
|
$67.07 M
|
$49.47 M
|
$46.61 M
|
$23.73 M
|
$32.51 M
|
$17.71 M
|
$13.02 M
|
$8.90 M
|
| Other Expenses |
$0.00 |
-$1,000.00 |
$1,000.00 |
$0.00 |
-$8,000.00 |
$0.00 |
$5,000.00 |
-$1,000.00 |
$7,000.00 |
-$442,000.00 |
| Operating Expenses |
$135.54 M |
$125.61 M |
$117.15 M |
$78.17 M |
$87.70 M |
$60.64 M |
$63.39 M |
$44.77 M |
$39.63 M |
$27.78 M |
| Cost And Expenses |
$140.83 M |
$130.15 M |
$121.56 M |
$80.25 M |
$90.03 M |
$61.11 M |
$63.85 M |
$45.21 M |
$39.95 M |
$27.87 M |
| Interest Income |
$3.98 M |
$798,000.00 |
$33,000.00 |
$168,000.00 |
$1.23 M |
$879,000.00 |
$424,000.00 |
$304,000.00 |
$166,000.00 |
$7,000.00 |
| Interest Expense |
$11.34 M |
$7.02 M |
$6.67 M |
$6.77 M |
$6.10 M |
$1.74 M |
$1.89 M |
$1.68 M |
$1.72 M |
$1.12 M |
| Depreciation &
Amortization |
$2.98 M
|
$2.11 M
|
$2.42 M
|
$2.77 M
|
$2.53 M
|
$2.29 M
|
$1.63 M
|
$881,000.00
|
$754,000.00
|
$547,000.00
|
| EBITDA |
-$66.42 M
|
-$61.91 M
|
-$75.62 M
|
-$146.10 M
|
-$77.74 M
|
-$55.95 M
|
-$59.87 M
|
-$42.14 M
|
-$37.27 M
|
-$26.98 M
|
| EBITDA Ratio |
-1.14 |
-1.51 |
-1.79 |
-3.6 |
-20.01 |
-29.27 |
-31.98 |
-22.8 |
-21.73 |
-35.66 |
| Operating Income Ratio
|
-1.41
|
-1.53
|
-1.79
|
-3.61
|
-20.3
|
-29.71
|
-32.2
|
-22.96
|
-21.83
|
-35.1
|
| Total Other
Income/Expenses Net |
$1.65 M
|
$7.62 M
|
$71.48 M
|
-$92.79 M
|
-$570,000.00
|
-$860,000.00
|
-$1.46 M
|
-$1.38 M
|
-$1.55 M
|
-$1.55 M
|
| Income Before Tax |
-$80.74 M |
-$71.04 M |
-$6.55 M |
-$155.64 M |
-$86.37 M |
-$59.98 M |
-$63.39 M |
-$44.70 M |
-$39.75 M |
-$28.65 M |
| Income Before Tax Ratio
|
-1.38
|
-1.38
|
-0.15
|
-8.94
|
-20.43
|
-30.14
|
-32.96
|
-23.69
|
-22.71
|
-37.11
|
| Income Tax Expense |
$0.00 |
-$7.62 M |
$4.25 M |
$4.00 M |
$3.56 M |
-$2.29 M |
$272,000.00 |
$798,000.00 |
$977,000.00 |
$130,000.00 |
| Net Income |
-$80.74 M |
-$63.42 M |
-$10.80 M |
-$159.63 M |
-$89.94 M |
-$57.69 M |
-$63.39 M |
-$44.70 M |
-$39.75 M |
-$28.65 M |
| Net Income Ratio |
-1.38 |
-1.23 |
-0.25 |
-9.17 |
-21.28 |
-28.99 |
-32.96 |
-23.69 |
-22.71 |
-37.11 |
| EPS |
-1.09 |
-0.83 |
-0.14 |
-2.63 |
-1.99 |
-1.51 |
-2.2 |
-1.8 |
-1.71 |
-2.69 |
| EPS Diluted |
-1.02 |
-0.83 |
-0.13 |
-2.63 |
-1.99 |
-1.51 |
-2.2 |
-1.8 |
-1.71 |
-2.69 |
| Weighted Average Shares
Out |
$79.83 M
|
$76.88 M
|
$76.39 M
|
$60.75 M
|
$45.27 M
|
$38.12 M
|
$28.82 M
|
$24.82 M
|
$23.24 M
|
$10.65 M
|
| Weighted Average Shares
Out Diluted |
$85.60 M
|
$76.88 M
|
$82.16 M
|
$60.75 M
|
$45.27 M
|
$38.12 M
|
$28.82 M
|
$24.82 M
|
$23.24 M
|
$10.65 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
